34.234.83.135
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Glaucoma

Glaukos submits new drug application to FDA for iDose TR

Glaukos has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time. iDose TR is intended to address...

Read More
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-